Liminatus Pharma, Inc.

LIMN

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001971387

None

No letter

2 of 14 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $512,795
Warnings	late filer, thin data not computable: dilution, short runway, degenerate inputs, distress, fortress balance sheet
Inputs computable	2 of 14
Graded from	filings received through Mar 31, 2026 228 days before the rescan; latest periodic filing 10-Q received Aug 14, 2026
Last close	$2.95 2026-11-12; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 31, 2026

Unless otherwise stated or unless the context otherwise requires, the terms "we," "us," "our," the "Registrant," the "Company" and "Liminatus" refer to refer to the business and operations of Liminatus Pharma, LLC, a Delaware limited liability company, prior to the consummation of the Business Combination (as defined below) and to Liminatus Pharma, Inc. and its consolidated subsidiaries (including Liminatus Pharma, LLC) following the consummation of the Business Combination. Furthermore, unless otherwise stated or unless the context otherwise requires, references to "Iris" refer to Iris Acquisition Corp, a Delaware corporation.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	not computable	(6.6%)			
a prior annual assets observation is required					
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 99.6					
Twelve-month failure probability	not computable	0.08%			
firm-wide XBRL shares cannot be assigned to one ticker class					
Altman Z double-prime	(412.35)	(0.31)	99.8	743	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	0.05x	2.96x	99.5	825	2025-12-31
Growth and financing					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 0					
Free cash flow growth, three-year compound	not computable	11.0%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	not computable	2.3%			
four annual observations are required; found 1					
Net share issuance, one year	not computable	2.4%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Late filer	found 2 NT 10-K/Q filings in the last eight quarters
Thin data	2 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-12 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(94.6%)	(1.5%)	1
Distance from 52-week high	(97.1%)	(32.0%)	1
EBIT to enterprise value	not computable	(1.8%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	not computable	0.29	
Sales to price	not computable	0.29	
Composite equity issuance, five years	not computable	19.1%	
Relative strength against the sector, log excess return	(3.09)	(0.18)	1

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	92 (10-Q received Aug 14, 2026)
Median daily dollar volume, 63 sessions	$81,303

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$10.2M	2025-12-31	2026-03-31	10-K	26-037933
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.0M	2025-12-31	2026-03-31	10-K	26-037933
3	assets	us-gaap:Assets	$512,795	2025-12-31	2026-03-31	10-K	26-037933
4	current assets	us-gaap:AssetsCurrent	$500,574	2025-12-31	2026-03-31	10-K	26-037933
5	current liabilities	us-gaap:LiabilitiesCurrent	$10.3M	2025-12-31	2026-03-31	10-K	26-037933
6	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$38.9M	2025-12-31	2026-03-31	10-K	26-037933
7	operating income	us-gaap:OperatingIncomeLoss	-$3.0M	2025-12-31	2026-03-31	10-K	26-037933
8	book equity	us-gaap:StockholdersEquity	-$9.8M	2025-12-31	2026-03-31	10-K	26-037933
9	liabilities	us-gaap:Liabilities	$10.3M	2025-12-31	2026-03-31	10-K	26-037933

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.